CryoCor completes trial enrolment:
This article was originally published in Clinica
Executive Summary
CryoCor has completed enrolment of more than 170 patients in a 12-month pivotal clinical study to assess the use of its cryoablation technology in atrial fibrillation. The device, also named CryoCor, was recently approved in the US for the treatment of right atrial flutter (see Clinica No 1268, p 2). The San Diego, California-based company said that it expected to file a PMA for the treatment of atrial fibrillation in late 2008, with approval anticipated in 2009.
You may also be interested in...
California Bill To Age-Restrict Sales Of Diet Pills Further Along Than Other States’ Legislation
CA, MA and NJ legislatures remain in session with bills active proposing regulations similar to NY law effective 22 April requiring retailers, including online, to ask for proof of age when customers buying consumer health products containing ingredients labeled or promoted for weight loss and bodybuilding benefits appear younger than 18.
CRN Has Standing For Steep Hill To Climb Challenging New York's Age-Restricted Sales
Federal judge finds “misreading of the legislation” in CRN’s argument that state “restricts access based purely on what has been said about the product or its ingredients.” But standing to challenge “means that only CRN is positioned right now to go before the court on behalf of industry,” says CEO Steve Mister.
Addition to Quest Alzheimer's Suite Looks For Biomarker P-Tau217
The test is being integrated into Quest’s AD-Detect portfolio for assessing the risk of Alzheimer’s. It is the third p-tau217 test to make news this month, after new breakthrough designations for Quanterix and Roche and Eli Lilly.